BTG Plc (the company or BTG) was founded in 1948. The Company is engaged in the commercialisation of novel technologies. The Company operates from offices in the Europe, North America and Japan. The Company has more than 50 years' experience in successfully commercialising important new technologies. BTG is a technology commercialisation company. The Company finds, develops and commercialises emerging technologies in the life and physical sciences. The Company’s business is structured around five areas: ageing and neuroscience; biopharmaceuticals; oncology; semiconductors; and IP-driven opportunities outside the four target areas. Ageing and neuroscience The focus of the ageing and neuroscience team is on finding, developing and commercialising pharmaceutical assets in the therapeutic areas of pain, neurodegeneration including Alzheimer's disease and multiple sclerosis, and obesity. BioPharmaceuticals The strategy of the biopharmaceuticals team is to invest in therapeutics, diagnostics and platform technologies that have the potential to accelerate the pharmaceutical value chain. Oncology BTG ultimately delivers products that can significantly improve the treatment of people with cancer. Semiconductor technologies, optoelectronics and nanotechnology The Company will focus on opportunities that offer strongly protected IP assets, building strategic and opportunistic partnerships that provide access to later stage rights. The portfolio is being built around key areas of low-power methodologies, advanced memories, system level integration, inter- and intrasystem communication and storage, fundamental materials and cell designs. In optoelectronics, the focus is on components and devices technologies that will enable the next generation systems, including lasers, LEDs, OLEDs, waveguides, modulators, filters, speciality fibres, and related materials and fabrication processes. BTG’s optoelectronics team is concentrating on technologies that provide a broad spectrum of commercialisation opportunities. The nanotechnology focus is currently on nanowires and photonic bandgap materials, and the team has excellent relationships with key researchers in these fields at the University of Lund, Denmark, and the University of Southampton, UK. BTG has commissioned a development programme for the lithium polymer battery, a technology from the University of Leeds, UK, to develop lighter, more powerful batteries for use in portable electronic equipment. Other technologies in development and commercialisation include: XMatchPROVW, a proven lossless data compression technology; a write head with preconditioning gap for magnetic media drives, which increases data density and media capacity; and Blue VCSEL, a blue vertical cavity surface emitting laser for high density storage, general lighting and biophotonic applications. BTG’s NQR explosives and drug detection technology is being used to develop an explosives detection device for use by airlines to monitor carry-on bags under an agreement between BTG licensee QRSciences and Lockheed Martin Corporation. Clients/Licensees The Company has made licensing agreements with a number of companies worldwide including: Abiogen Pharma, Alizyme, Apotex, AstraZeneca, Bausch & Lomb, Biomet Inc, British Telecom, Caliper, CeNeS, Chiron, Cisco, Cytokine PharmaSciences, Eli Lilly and Company, Forest Laboratories, France Telecom, GE, Genentech, Inc., Hitachi, Ilex Oncology, Immunex Corporation, Johnson & Johnson, Lucent Technologies, NewLife Technologies, Oki Electric and NEL, Pharmacia, Philips International BV, Proteus International plc, Resusitek, Royal Bank of Canada, Shimadzu, Siemens, Smith & Nephewl, Stryker, Toshiba, US Genomics, Wright Medical Technology, Wyeth and Zimmer.
btg plc (BTG:London)
5 Fleet Place
London, EC4M 7RD
Phone: 44 20 7575 0000
Fax: 44 20 7575 0010www.btgplc.com
|Richter Gedeon Nyrt||4,247||+23.00|
|Merit Medical Systems Inc||$15.02 USD||0.00|
|Pfizer Ltd/India||1,358 INR||0.00|
|RPX Corp||$16.80 USD||-0.25|
|Skyepharma PLC||247.75 GBp||-1.25|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.